Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

$ PRICE - $ 2,000.00$ 6,000.00

$ PRICE - $ 2,000.00$ 6,000.00
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,000.00
FacebookTwitterLinkedinEmail

Report

Description

Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Idiopathic pulmonary fibrosis primarily occurs in older adults and disease confined to lungs only. Symptoms may include weight loss, pneumonia, fatigue, low-gradefevers and others. Idiopathic pulmonary fibrosis diagnosis is done through imaging techniques, lung biopsy,laboratory tests and others. Currently, no medications are proven to effectively treat idiopathic pulmonary fibrosis. Generally, Azathioprine, Prednisone,and N-acetyl cysteine are used alone or combination for the treatment.

 

Segmentation:

By route of administration, Idiopathic Pulmonary pipeline drugs are segmented into

  • Inhalation
  • Parenteral
  • Others

By Trial Phase, Idiopathic Pulmonary Fibrosis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3

By Company, Idiopathic Pulmonary Fibrosis pipeline drugs are segmented as:

  • Johnson & Johnson Services, Inc. (U.S.)
  • ImmuneWorks, Inc. (U.S.)
  • Hoffmann-La Roche AG (Switzerland)
  • Celgene Corporation (U.S.)
  • Biogen, Inc. (U.S.)
  • FibroGen (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Promedior, Inc. (U.S)

 

Space Analysis:

Many of the research studies and ongoing trials are studying the various drugs and lead molecules to treat the idiopathic pulmonary fibrosis. The recognition of new factors contributing to the pathogenesis of idiopathic pulmonary fibrosis has led to the development of novel approaches to treat idiopathic pulmonary fibrosis.

  • In August 2017, FibroGen, Inc. announced positive topline results from the company’s Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).
  • In October 2017, Prometic Life Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBI-4050, a clinical candidate in development for idiopathic pulmonary fibrosis (IPF).

 

Report Description:

Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Idiopathic Pulmonary Fibrosis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Idiopathic Pulmonary Fibrosis disease pipeline drugs development. This report studies the dynamics of the Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs i.e. drivers, challenges,and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Idiopathic Pulmonary Fibrosis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis of each drug candidates in the clinical trial phases

 


Location

GEOGRAPHY

PBI Location Map

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Johnson & Johnson Services, Inc. (U.S.)
  • ImmuneWorks, Inc. (U.S.)
  • Hoffmann-La Roche AG (Switzerland)
  • Celgene Corporation (U.S.)
  • Biogen, Inc. (U.S.)
  • FibroGen (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Promedior, Inc. (U.S)

Report

Ask An Analyst

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Description

Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Idiopathic pulmonary fibrosis primarily occurs in older adults and disease confined to lungs only. Symptoms may include weight loss, pneumonia, fatigue, low-gradefevers and others. Idiopathic pulmonary fibrosis diagnosis is done through imaging techniques, lung biopsy,laboratory tests and others. Currently, no medications are proven to effectively treat idiopathic pulmonary fibrosis. Generally, Azathioprine, Prednisone,and N-acetyl cysteine are used alone or combination for the treatment.

 

Segmentation:

By route of administration, Idiopathic Pulmonary pipeline drugs are segmented into

  • Inhalation
  • Parenteral
  • Others

By Trial Phase, Idiopathic Pulmonary Fibrosis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3

By Company, Idiopathic Pulmonary Fibrosis pipeline drugs are segmented as:

  • Johnson & Johnson Services, Inc. (U.S.)
  • ImmuneWorks, Inc. (U.S.)
  • Hoffmann-La Roche AG (Switzerland)
  • Celgene Corporation (U.S.)
  • Biogen, Inc. (U.S.)
  • FibroGen (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Promedior, Inc. (U.S)

 

Space Analysis:

Many of the research studies and ongoing trials are studying the various drugs and lead molecules to treat the idiopathic pulmonary fibrosis. The recognition of new factors contributing to the pathogenesis of idiopathic pulmonary fibrosis has led to the development of novel approaches to treat idiopathic pulmonary fibrosis.

  • In August 2017, FibroGen, Inc. announced positive topline results from the company’s Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).
  • In October 2017, Prometic Life Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBI-4050, a clinical candidate in development for idiopathic pulmonary fibrosis (IPF).

 

Report Description:

Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Idiopathic Pulmonary Fibrosis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Idiopathic Pulmonary Fibrosis disease pipeline drugs development. This report studies the dynamics of the Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs i.e. drivers, challenges,and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Idiopathic Pulmonary Fibrosis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis of each drug candidates in the clinical trial phases

 


Location

GEOGRAPHY

PBI Location Map

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX